An earlier study reported that when combined with PSA, Trinity Biotech’s EpiCapture correctly identified all high-grade prostate cancers in the cohort, indicating a strong sensitivity signal for aggressive disease. While the absolute cohort size and specificity trade-offs weren’t disclosed here, that headline performance sets a high bar for the assay’s next phase of validation.
The company has now entered a strategic collaboration with an unnamed bioinformatics firm to run advanced analyses on clinical trial datasets for EpiCapture, a PCR-based methylation liquid biopsy designed to monitor risk of progression to aggressive prostate cancer. The work is aimed at refining the classifier, deepening analytical credibility, and preparing the evidence package for regulatory submission and commercial rollout. Trinity notes the test is in late-stage development and will leverage its New York State–certified reference laboratory to support development and potential launch.
The move reads as an evidence-to-utility push in a crowded, scrutinized space. Payers and guideline bodies have raised the bar from analytical performance to demonstrable clinical utility—fewer unnecessary biopsies, better risk stratification in active surveillance, and clearer decision thresholds alongside PSA and MRI. Outsourcing heavy-lift bioinformatics suggests a plan to lock the algorithm for regulatory review, stress-test it across diverse cohorts, and address drift and generalizability—areas where many epigenetic assays stumble. It also gives Trinity optionality on the regulatory path: near-term laboratory deployment under state and CLIA oversight while building toward an FDA IVD submission, a pragmatic hedge as federal oversight of LDTs tightens.
For research sites and urology networks, a non-invasive progression monitor could streamline active surveillance visits, reduce repeat invasive biopsies, and fit into decentralized follow-up models. The operational lift will sit in pre-analytical rigor: standardized collection, handling, and timing relative to PSA and MRI; chain-of-custody processes; and integration with site LIS/EHR for longitudinal tracking. CROs with diagnostics and SaMD experience will see demand for prospective, multi-center utility studies that capture biopsy upgrading, adverse pathology at prostatectomy, and procedure reduction as endpoints. Regulators will focus on locked-model documentation, assay reproducibility across lots and instruments, and protocolized handling of out-of-range or indeterminate results. Vendors in the ecosystem should expect requirements for clean interfaces to urology EMRs and automated reporting that aligns with guideline-based pathways.
The key test for EpiCapture is no longer whether it can flag aggressive disease, but whether it can change management at scale. Watch for a prospective, multi-site validation with predefined cutoffs, decision-curve analysis, and head-to-head performance versus incumbent tools used in surveillance and pre-biopsy triage, including MRI-based pathways and other molecular tests. Evidence of reduction in unnecessary biopsies without missing upgrades, performance retained across racial and age subgroups, and durable accuracy across operators and sites will drive payer decisions and guideline inclusion. On the regulatory front, clarity on whether Trinity pursues an initial LDT deployment before IVD clearance will signal time-to-revenue expectations and evidence depth. The principal risks are overfitting masked by retrospective curation, dependence on combined scoring with PSA that may limit stand-alone claims, and the operational burden of maintaining a locked assay while updating pipelines. If the forthcoming analyses show utility beyond strong sensitivity, this collaboration could convert a promising signal into practice-changing adoption in active surveillance workflows.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
